All right. Good afternoon, everyone. Thank you for joining us today in London at the Jefferies Global Healthcare Conference. My name is Faisal Khurshid. I am one of the senior biotech analysts here at Jefferies. Really pleased to have with us today, Will Lewis, CEO of Insmed. We have a lot of interesting stuff to get through. Will, why don't you kick it off for us?
Well, let me just say that I appreciate the opportunity to be here and tell you that we have just completed or almost completing one of the most transformational years in the company's history with the successful launch of BRINSUPRI, which I know everyone has been tracking. That product has now cleared $1 billion and is a blockbuster officially, by that standard. But we believe this is just the beginning, and I think importantly, what will drive it in the future is the opportunity to address the balance of patients we have not yet reached. We are very mildly penetrated into this market opportunity. We have said there are 500,000 patients in the U.S. alone, 250,000 of which have two or more exacerbations, and we put tens of thousands of patients on drugs successfully, but that means we are basically 10% penetrated.
We have a lot further to go, and that is before we start to step into some of these additional populations which are really monstrous, like the COPD and asthma comorbid population. That is just for BRINSUPRI. ARIKAYCE, now in its eighth year of launch, still growing healthily, is about to expand to frontline. That is a sevenfold increase in addressable market. That is just our first two programs. Behind that, we have a very rich and growing pipeline and a very active BD effort. So, I think we are well poised for another breakout year in 2027.
Got it. All right. Well, I am going to ask an easy question and then a hard question. Maybe for the easy one, if you were to take a step back, right, and just kind of talk to investors like a year or two ago and say, "Bronchiectasis, a disease that has never had any pharmacologic treatment, you are going to come in and do $1 billion plus in your first full calendar year," people would say, "That seems like a long shot." What do you think you have done right that has enabled that success?
Well, I appreciate the question, and it sounds like a softball, but the truth is when we-
Yeah, we got the hardball coming after.
I am sure we do. I expect no less. But look, when we did the launch of ARIKAYCE, which is a drug device inhaled liposomal encapsulated antibiotic, there is no less interesting drug to try to launch into a market, even if it is first in disease. It had a 30% dropout rate. It is a drug device combination. It is used in elderly people that need a lot of handholding, and we got that to be a top 10 launch non-oncology rare disease of all time. So, we used the learnings from that, educating the market about the disease state, a year prior to launch and approval of the drug to really set the stage for the best possible uptake.
The honest truth is, as exceptional a job as the commercial team has done, and they have done an exceptional job, the greatest strength of this opportunity is the drug itself. This drug makes people feel better in many cases. That is actively reported in social media. The physician community knows about that. That encourages uptake of the drug from this moment where we are past experimentation stage and we get into really the push part where physicians decide to give this drug as a default treatment. At places like National Jewish Health in Denver, one of the best pulmonary hospitals in the country, they are no longer looking for patients. They are looking for scheduling opportunities. They are booked out months in advance, and every patient that is brought in with bronchiectasis, is offered BRINSUPRI. So, this is just the beginning.
Got it. In terms of the underlying execution of the company, the launch trajectory, I think it's objective to say that things have gone quite well. The drug has reached an amazing milestone. However, it's been a pretty dramatic year for your stock and from the investment perspective. Can I just get your reflections on that?
This is the hard question? Well, I'll just tell you, we can always do better at communication, and I think when you're going with a first-in-disease drug like we were, we're trying to give as much insight into what was going well with the drug as we possibly could, and at times, that extra detail, I think, was confusing to the marketplace. What we needed to do was sort of step back and just establish what it was going to do quarter after quarter. And every quarter this year, we've beaten and raised guidance. If you look at where we are now, we're estimating that we'll do $1.35 billion-$1.4 billion for this drug in its first full year of launch, which is extraordinary. That makes it a top 20 launch of all time in any therapeutic area.
It is really a blockbuster, and it's on its way to being a mega blockbuster, which we define as greater than $5 billion in peak sales. We've estimated it will be at least $7 billion, and that does not include the comorbid population. It does not include ex-U.S. There's an awful lot left for us to grow here, and I think as we continue to put the quarters up, the nuance of one point of communication or another or one metric or another, falls into the background and is just overwhelmed by the performance.
Got it. Without getting into the specifics, obviously, like any drug launch, it's essentially a formula of three things, right? It's getting patients on drug, keeping patients on drug, and the price that you have. Can you just talk at a high level about what you have seen year to date on those three categories and what you expect through 2027?
Sure. Getting them on drug, the last and only public guidance we provided was that we had a 90% approval rate from insurance, which is extraordinary. Best benchmarks would be in the 70%. We are way out front on that one, and that is holding up pretty well. I expect it to continue to do so. I do not think there will be a big margin structure change next year as a result of renegotiation or anything like that. Market access is really good. We get patients on drug once they are approved, very rapidly, with a high percentage of the time. The actual conversion of patients is extremely good with this launch. Keeping them on drug.
We brought up the point of persistence at the end of the first quarter, I think it was, and it sent Wall Street in a tailspin because they were worried they did not understand what it meant. They were concerned that the number we were quoting was high or not attractive. What people now understand, I think, is that persistence is one of the cornerstones of strength of this launch. We are at a place now where patients are going on drug and staying on drug because they feel better on drug, and that is an extraordinary boon to the future of this launch. We are talking about, p robably the best way to put this in perspective is we had hired McKinsey to do an assessment of our launch plan before the drug was launched, and they had told us that our persistence estimate that we were targeting was crazy high.
We are 20 percentage points above what McKinsey had said would be the appropriate benchmark, which should give you some idea of how strong that is. Then your final question, or final element, get them on drug, keep them on drug-
Price.
-and price. The price for this is in the $80,000 range. It is a little bit above that. Importantly, that has carried forward into international locations. We now get a price north of $ 50,000 in Japan. Japan is launched just recently. There are 150,000 patients in Japan. Our team over there has done an exceptional job with ARIKAYCE, coming to account for almost 25% of our sales at times. As we look forward to the future of Japan, we have 200 folks over there. We are adding another 50 sales reps, which will really kick in by the middle of next year.
I think a tailwind for us going into next year is going to be the Japan launch for BRINSUPRI, the Japan launch for the full frontline label of ARIKAYCE, which we presume we will get in the first half of the year, and the U.S. launch of the frontline of ARIKAYCE, which we will get in the first half of the year. Actually, our PDUFA date is the end of January. All these things are certainly wind in our sails. To that, I would add perhaps the thing that we sometimes find irritating, which is direct-to-consumer advertising. But the fact of the matter is it works, and we are going to be launching that basically in a week's time in the U.S. for the first time. That usually returns about threefold what you invest in it.
While we're not going to disclose what that is at the moment, we're going in early with an aggressive campaign. We'll see how it does. We would expect to see that end of first quarter or second quarter in terms of contribution to our revenue, but that will be something that we'll continue to revisit and reinvest in more aggressively if we see it as successful as we expect it will be.
Got it. I just want to double-click on that point that you made on persistency, because I think you're giving us a really fascinating inside look. You said you had a launch plan, you had a certain persistency benchmark. McKinsey said it's got to be way lower. You crushed the McKinsey estimate. Did you crush your own estimate?
We did.
Awesome.
We still are.
Then in terms-
Basically, the profile of this, just to put kind of a visual, especially for those listening and not in the room, it drops a little bit right at the beginning when you first go on drug. If you are going to drop off this drug, it is really within the first six to eight weeks, and then it flatlines almost, perfectly horizontally into the future. It tails over time, but it is not a dramatic drop-off. You do not see a sawtooth pattern or anything like that. You get on the drug, and then you pretty much stay on it. What is interesting about that is the people who are dropping off the drug early, this is a persistent and irreversible disease.
What is going to happen is that they are going to have another flare or another exacerbation, and when they do, they are going to go into the hospital, and the physician is going to say to them, "There is only one drug approved to treat your condition and to give you a shot at either reducing or delaying or reducing the severity of your exacerbation, and that is BRINSUPRI. So this time, go on it and maybe try and stay on it for a longer period of time." One of the main reasons people do drop off this drug is not just the side effect profile, because that is quite mild. I will remind everyone that the dropout rate was higher in placebo than it was in the treatment arm in the phase III.
People drop off because they don't always feel better right away, and they have that expectation, because if you read about this on social media, this drug gets talked up quite a bit. So the message to them is, "Wait a little longer. You will begin to feel benefit over time, possibly." We can't detail to that because it's not in the label, but that is clearly what the experience is with patients. The louder we can make the megaphone, in front of the physicians who talk about this, the better for everyone.
Got it. Then on new starts, what is the trajectory that you expect going kind of through the next kind of 12 - 18 months? Then with respect to DTC, is that a vehicle more to kind of bolster the trajectory that you're on, or is it to accelerate that trajectory?
So it's to accelerate it. What I would say about new patient starts is, at this point in a launch, you would normally expect new patient starts to flatline or maybe even begin to decline a little bit. My expectation is that next year, they're actually going to go up, and they'll go up by perhaps a few hundred a quarter, not like 1,000, but it'll continue to trail up. That's because I think you're going to see a combination of forces. Yes, the DTC, yes, the greater knowledge of this drug. Our own sales force is going to be able to go out and say, "Look, tens of thousands of patients have been on this drug, and thousands of physicians have written this prescription, and patients are really benefiting.
Your decision not to give the drug is actually ensuring that your patient is going to have an exacerbation, is going to have that permanent damage done to their lung. Are you sure you don't want to put them on the drug?" I think we're going to begin to slowly expand so that instead of it becoming a trial balloon, it becomes the default treatment. Someday, in the not-too-distant future, I expect that all physicians and hospitals will begin to behave like National Jewish does in Denver right now, which is any patient who is brought in and diagnosed with bronchiectasis is offered BRINSUPRI.
Got it. The other big thing happening next year in the bronchiectasis space is that we will see phase III data from Boehringer Ingelheim. They have a DPP1 inhibitor as well. Can you just talk about, from a competitive preparedness standpoint, what your perspective is on that?
Yeah, sure. Let's start out with the most important point. The enemy here is not another company. The enemy here is the disease. We welcome their arrival into this market, and we hope that their drug is very successful. We will obviously be educating people about the differences between the drugs, just as they will, but this will, in aggregate, benefit the patients and physicians worldwide. Typically, when you see a second drug come into a large market opportunity like this, it tends to make the pie bigger instead of splitting it up in a more nuanced way. That will come later with other entrants. But right now, as the first in market with a couple of years head start, we are in a very strong position, and we have made a lot of investments to augment that. Longitudinal data, we are running a 3,000-patient study with the EMBARC registry in Europe.
We are running a 1,000-person study in the U.S. All of this is designed to add clarity and evidence about what our drug does, including reversing the disease process. I will just put a footnote here. We did a 100-patient imagery study in our phase III ASPEN program, and we saw that, it appears that this symptomatic benefit, may in fact be linked to actual anatomic changes in patients, and that the imagery seems to document that. So we are now doing that at scale to try to be able to put that into, if not the label, certainly in publications. The sub-study from the ASPEN study will be submitted to a publication, so we are excited to see that arrive. It is just more evidence of the power of this drug in this particular disease state. It is very positive.
Got it. Okay. I want to talk about this idea of the comorbid COPD asthma opportunity. That is obviously one of the next big drivers that is potentially here. Can you talk a little bit about that, and in particular, when should we start seeing that within the launch, or are we already?
Let me be really clear about one thing. Everybody in this room, when you leave, if there's one thing you leave with, it's the awareness that the single biggest driver of value in our company in the next three to five years is the ability to harness the COPD and asthma comorbid population. Putting the numbers around that, our total addressable market now, we estimate in the U.S. at 500,000 patients, 250,000 of which we think have two or more exacerbations and represent the initial target for our launch. There are 32 million people in the U.S. with asthma and COPD, and the best back-of-the-envelope guess right now is that about 20% of those are comorbid with bronchiectasis but have not been diagnosed as such. Some portion of that, for sure, are going to be highly symptomatic and potentially will benefit from BRINSUPRI.
The work to turn the oil tanker to get those patients into the top of the funnel has just started in earnest, and we made great inroads. We're already in the COPD GOLD guidelines, calling for high-res CT scan if you have COPD and are still symptomatic and not effectively treated to see if you have bronchiectasis, and if you do, it calls for you to be treated with BRINSUPRI. The opportunity to access this, which is obviously multiples the size of the market we are targeting at launch, is enormous. When we talk about the addressable market and what it yields in terms of peak sales, we have estimated that that number is north of $7 billion just on the 250,000 patients. If we can add these additional patients into the top of the funnel, that obviously could grow, and that's a very exciting opportunity.
It's an enormous task to undertake. We actually have a separate group dedicated to it inside the company. We treat it like a separate launch, if you will, a second launch in this indication. But the opportunity there is really very substantial. It's one that's almost daunting, I would say, but we're resourcing the heck out of it, and we've got an absolute top-shelf team that's pursuing it. We should see, the first information, from that in the middle of next year. Let's document this market with greater detail. We're retroactively looking at CT scans and COPD patients and asthma patients right now. We hope to document that and be able to provide that in publication next year so that people can really put their arms around how big is this potential market opportunity.
We have a number of different efforts that are being made in parallel to try to educate COPD and asthma physicians about this, and also to enable our therapeutic specialists to address this opportunity in an appropriate and compliant way.
Got it. Will, just to kind of like bring it up to a higher level, it sounds like for next year, you are going to continue to expect to see very strong growth, bolstered and accelerated by your DTC as well. As we get deeper into 2027 and 2028, we will get the comorbid opportunity, and then as we get into 2029, TPIP will come into the picture as well. Is that a fair kind of high-level framing to think about 2027, 2028, 2029?
Yes, to that, I would also add that finally, what we used to call our fourth pillar, but our research pipeline is going to start to read out and become commercially relevant. We have a gene therapy in DMD. We have a gene therapy in ALS. We have one coming in Stargardt and RP and other indications. We would expect that if the DMD data next year is strong, we will go right into a pivotal for accelerated approval, and that means that that therapy could hit the market at or around the time that TPIP does. These are not only interesting data points and future contributors, they are proximate contributors because of the accelerated pathway that may be available to the gene therapy, presuming that the data is strong enough. That is true for every drug we are developing, first or best in class.
Similarly, we are going into phase II in IPF with our INS1148 next year. This is a fantastic compound that our business development team found, and I am super excited about it because while it is being tested in INS1148, pardon me, in IPF, it will also be tested in PPF and potentially other fibrotic diseases. For those who are familiar with the science, this is the c-Kit pathway. It targets Stem Cell Factor 248, but does not disturb Stem Cell Factor 220, which is involved in the homeostasis. So, you influence the inflammatory pathway and potentially the pro-fibrotic pathway, but without disturbing the homeostasis. So it is a very exciting opportunity. If we can get that into a subcutaneous form, that could go into asthma. So there is a lot coming.
Got it. I want to come back to that, but we got to get to TPIP. When I talk to investors about TPIP, the things that people push back on are, what is the timeline to getting these phase III studies? What is the litigation risk here? What is the differentiation versus the product that is out there? What is the competitive landscape? This leads to investors being a little reluctant to give you more credit for TPIP. What do you say to that?
Yeah, I think people probably are reluctant on TPIP because they're more near-term focused. These programs, all four phase IIIs that we're running right now, three of them we have clinical data for already. So we have a decent idea that they are de-risked. The fourth one is a logical extension of, one of the others. Let's take each in turn. PAH, we've already put out phase II and open-label phase II extension data that goes out a year. Just to highlight that, we're looking at a 55-meter walk, six-minute walk improvement. We're looking at NT-proBNP reductions north of 60%. These are markers of right heart stress. We're looking at pulmonary vascular resistance reductions of 35%. To put that in perspective, that's just at or slightly better than sotatercept, which is currently at a $3 billion run rate treating the same disease. That's just PAH.
We'll have another year's data coming out this next year to update, so you'll have two years of longitudinal data with this drug. Our PH-ILD phase II-A study was very encouraging. Time to clinical worsening, directionally improved. So we're super excited about that. You're asking about the enrollment of the studies. PH-ILD, the first one we launched, is six months ahead of schedule. So, it's great that I've got all kinds of enthusiasm for this. What really matters is, what is the physician community doing with this drug and how are they perceiving it? It is very clear that they are extremely excited about it. We believe it's going to be the prostanoid of choice. We understand that there are others who have prostanoids who will be threatened by this, and I'm sure they'll use everything at their power.
I like to keep everyone focused on the disease state and what role we can play as a drug to contribute to what is going to be a combination market. We believe we are going to be the prostanoid of choice to be paired with sotatercept or perhaps other drugs. Just as a perhaps a final point, in our open-label extension study in PAH, we got 80% of the patients to a functional class I or II status. That means they're basically asymptomatic for a fatal disease. It's a remarkable accomplishment for a drug whose mechanism of action has been known and understood for a long time. It is the, and I can say this because I had nothing to do with it, the brilliance of the reformulation, this pro-drug that has been developed, that enables that.
All of these measures I'm describing for you, they are at trough levels, 24 hours after the drug is administered, not at peak levels, when all the other drugs that have been tested in this sector are tested. When we do our phase IIIs, we're going to measure at peak. Chances are our data may even be better than what we've reported so far.
Got it. As we get into next year, you guys have guided to achieving break-even or profitability next year. You're also at the same time talking about the maturation of the pipeline and bringing some of these things like DMD into a potential pivotal, things like that. How do you think about sort of the balance of bridging the profitability and growing the cash flow generation versus reinvesting that into the pipeline?
Yeah. So next year begins the start of thinking about that in a very systematic way. I would tell you that the growth of the revenue, my expectation is, will be so strong that regardless of how aggressive we get in supporting the pipeline, we're still going to make it to cash flow positive next year, and we will remain there once we cross. I don't see a reason why we'd go back. I think that the growth rate on the revenue is going to continue. Just to put it out there, I've said I think we will do north of 20%, compound annual growth for the next 10 years at this company, off of a base that is almost $2 billion this year, off of three different drugs with multiple potential indications.
I challenge you to find another company in the mid-cap space that has that kind of profile. We're in a very fortunate position. Our first three drugs have all worked. That's a rare thing in biotech, as we know. We don't take it for granted. That's why we're investing and have been for the last four years in our pipeline across four different technology platforms, because we have to have an answer to the question of what's next. We think we will starting next year.
Got it. As you're kind of, here in London, I think you have an insanely packed schedule today. What are the things that you're picking up on that, you think investors under-appreciate or misunderstand about the Insmed story?
I think they understand the story. There is some caution that came from our, I guess what would be fairly described as foot faults in some of our communication. I would not put that entirely on our team. I think some of it is also misunderstanding of what this drug represents and where it is going to go. To put out $1.35 billion to $1.4 billion in your first year of launch, is a top 20 of all time in any therapeutic area, is extraordinary by any objective measure. Again, I say it because I had nothing to do with it. It was the commercial team. But what it portends for the future of this company is a fabulous profile of revenue and earnings growth that is going to be hard to challenge and which is already diversified.
The excitement that I feel is not just that we are going to continue to execute, but that our pipeline will finally start to reveal itself and show additional contribution to that revenue growth trajectory over the course of the next five to 10 years.
Got it. Then maybe just wanted to kind of like wrap us up. I mean, you are here, you have this packed schedule today. You are here solo dolo. No CFO, no IR. You are reshaping a bit of the management team and the leadership, the investor-facing side of it. You are reshaping your board. As you are kind of going through that process, what are you solving for and what does kind of this next iteration of Insmed under your leadership look like?
It is a little bit of an unfair characterization on my part, but if I were to super simplify, thinking about the last three to five years, it was really about accessing capital and storytelling, putting together the resources needed to hopefully get approval and launch these drugs. The next three to five years are all about maximizing that opportunity, beginning to think about the efficiency of the income statement, making sure that our bottom line is not anything but growing and up to the right, and thinking about how do we do business development in a way that will complement what we have. We are very fortunate that we did business development early, and we keep doing it now, but we do not have to do it. We are not in a position where we need anything from the outside. If we choose to bring it in, fantastic.
But we have a very robust pipeline that is going to be coming to fruition. I think the people that we're bringing on board, the most recent board members, they're going to help us do the same thing we've been doing, but at a whole other level better, and the same goes for anyone on the management team. By the way, we wish Sara the best. I know you're going to, probably see her again, my prediction, as a CEO, but don't tell anyone that. We'll just keep that our secret. I think that the rest of the management team is going to make their own choice about whether they want to be in for this next chapter or not. The decision to part ways with a company is not always driven by some kind of animosity or problem, situation.
In fact, we are sitting with an embarrassment of riches. People have worked at this company for 10 - 15 years. Yes, they've made a lot of money, and they make different life choices. That's possible. It's perfectly fine. We will be ready for the next three to five years and beyond, by bringing and ensuring that the people we have at the leadership, are prepared to run through the walls the way the people did for the last 15 years.
Awesome. Thank you, Will. I really appreciate your candid remarks. Thank you, everyone, for joining.
Thank you.